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MemoryTranscription factors are known to play multiple roles in cellular function. Investigators report that factors such
as early growth response (Egr) protein and nuclear factor kappa B (NF-κB) are activated in the brain during
cancer, brain injury, inflammation, and/or memory. To explore NF-κB activity further, we investigated the
transcriptomes of hippocampal slices following electrical stimulation of NF-κB p50 subunit knockout mice
(p50−/−) versus their controls (p50+/+). We found that the early growth response gene Egr-2 was upregulated
by NF-κB activation, but only in p50+/+ hippocampal slices. We then stimulated HeLa cells and primary cortical
neurons with tumor necrosis factor alpha (TNFα) to activate NF-κB and increase the expression of Egr-2. The Egr-2
promoter sequence was analyzed for NF-κB binding sites and chromatin immunoprecipitation (ChIP) assays were
performed to confirm promoter occupancy in vivo. We discovered that NF-κB specifically binds to an NF-κB consen-
sus binding site within the proximal promoter region of Egr-2. Luciferase assay demonstrated that p50 was able to
transactivate the Egr-2 promoter in vitro. Small interfering RNA (siRNA)-mediated p50 knockdown corroborated
other Egr-2 expression studies. We show for the first time a novel link between NF-κB activation and Egr-2 expres-
sion with Egr-2 expression directly controlled by the transcriptional activity of NF-κB.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Transcription factors such as early growth response (Egr) protein
and nuclear factor kappa B (NF-κB) play multiple roles in normal and
pathological cellular function (Baldwin, 1996; Bhattacharyya et al.,
2011; Ghosh et al., 1998; Gomez-Martin et al., 2010). These roles in-
clude immune responses, cancer, inflammatory cascades, brain injury,
and memory, to name a few. For example, Egr-2 and Egr-3 are nega-
tive regulators involved in T-cell induction (Safford et al., 2005). In
addition, deficits in Egr-2 appear to cause conditions such as congen-
ital hypomyelination neuropathology (Kamholz et al., 2000). In can-
cer cells, elevation of NF-κB activity is often seen. NF-κB has alsoearch, 351 Tache Ave./R4050,been documented as a central player in inflammatory responses. In
addition, a growing body of knowledge implicates Egr and NF-κB activity
in the nervous system (Albensi andMattson, 2000; Beckmann andWilce,
1997; Mattson, 2005; Mattson and Camandola, 2001; O'Donovan et al.,
1999). However, how Egr and NF-κB activity might be regulated in
some coordinated fashion is unknown.
Transcriptional regulators of the NF-κB family consisting of p65 and
p50 subunits promote the expression of over 100 known target genes,
many of which are active in the host immune response (Ghosh et al.,
1998). In fact, current knowledge of NF-κB target genes in the nervous
system relies mostly on genes identified in the immune system (Pahl,
1999). In recent microarray studies, several new tumor necrosis factor
(TNF)-responsive genes have been identified in a human glioblastoma
cell line (Schwamborn et al., 2003) as well as 17 genes regulated by
p50 in the mouse hippocampus upon treatment with trimethyltin, a
neurotoxin (Kassed and Herkenham, 2004). In the CA1 region of the
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term memory consolidation and 12 of these genes contain NF-κB c-Rel
binding sites in their promoters (Ahn et al., 2008). In addition, our prior
work (Albensi and Mattson, 2000) demonstrated that NF-κB plays a role
in synaptic plasticity in vitrowhereby we stimulated Schaffer collaterals
in mouse hippocampal slices at high frequency (100 Hz) and induced
long-term potentiation (LTP), an experimental paradigm of memory,
whichwas blocked by administration of NF-κB decoyDNA (an inactivator
of NF-κB). Our recent work has also shown that NF-κB p50−/−mice have
deficits in LTP in vitro and impairments in long termmemory asmeasured
in the Morris water maze (MWM) (Oikawa et al., 2012).
The literature also suggests that immediate early gene (IEG) families,
such as Fos, Jun, and early growth response (Egr)-1 play important roles
in brain function (Dragunow, 1996; Miyashita et al., 2008). Egr genes en-
code transcription factors and are composed of fourmembers: Egr-1, Egr-
2, Egr-3, and Egr-4. In brain tissue, Egr gene family members show a sim-
ilar regional profile of basal expression. Distinct basal nuclear expression
of Egr-2 is prominent in layers II and III of the neocortex, but sparse in
layers IV and VI. In the hippocampus, pyramidal cells of the CA1–CA3 re-
gions express Egr-2 protein but little immunostaining is seen in the den-
tate gyrus (Herdegen et al., 1993a; Williams et al., 1995). To date, little is
known about the functional role of Egr-2 in the adult brain.
The objective of this study was to identify the activity of NF-κB p50-
dependent target genes involved in responses to electrical stimulation
using a range of cell andmolecular biologymethods. Analyzing the reg-
ulated activity of transcription factors may hold importance for under-
standing cell function in general and nerve cell function in particular.
Here we show a novel link between the activation of NF-κB and Egr-2
expression in HeLa and neuroblastoma cells and in primary neurons.
These data suggest that the expression level of Egr-2 is directly con-
trolled by the transcriptional activity of NF-κB.
2. Results
2.1. Egr-2 expression in stimulated NF-κB p50+/+ slices
To evaluate the transcriptomes fromhippocampal slices we used the
Affymetrix GeneChip®microarray system.We found that several genes
were upregulated specifically in theta-burst stimulated p50+/+ slices
(Table 1). In particular, Egr-2 showed a 2.83 fold increase in p50+/+
stimulated slices, but not in p50−/− stimulated slices. Subsequent ex-
periments focused solely on Egr-2 given its prior implication in synaptic
plasticity and memory (Cole et al., 1989; Williams et al., 1995; Worley
et al., 1993; Yamagata et al., 1994).
2.2. Egr-2 mRNA and protein expression in TNFα-treated cells
Since our microarray data suggested that Egr-2 expression was NF-κB
p50-dependent, and because TNFα is a well-characterized activator of
NF-κB signaling (Dolga et al., 2008), we examined Egr-2 expression fol-
lowing administration of TNFα. To assess the time-dependent effect of
TNFα treatment on Egr-2 mRNA expression (Fig. 1A), HeLa S3 cells
were exposed to mouse TNFα (5 ng/ml) for 0, 0.5, 1, or 3 h. The HeLa
S3 cell line, a human cervical carcinoma cell line that is insensitive toTable 1
Genes up-regulated in theta-burst stimulated CA1 hippocampal slices from p50+/+ mice, but
crease in expression for the p50+/+ group andnodifference in expression in the p50−/− group. E
slices with those from unstimulated slices.
Probe set ID Accession number Description
1427683_at gb:X06746.1 Egr-2 (Krox-20)
1459372_at gb:AV348246 Npas4 (neuronal PAS domain pro
1437118_at gb:C77542 Usp7 (ubiquitin specific peptidas
1437221_at gb:BB702377 Rrm2b (ribonucleotide reductase
1440801_s_at gb:BB391602 Adrbk2 (adrenergic receptor kin
1450120_at gb:NM_018733.1 Scn1a (sodium channel, voltage-TNFα apoptotic activity (Sekine et al., 2001), is an ideal cell line for
TNFα applications. We also used HeLa cells to test our hypothesis in a
non-neuronal cell line. Our results show that the expression of Egr-2 is in-
creased approximately 60 fold at 30min after TNFα treatment, ~150 fold
1 h after TNFα treatment, and ~3 fold 3 h after TNFα treatment (versus
control). Increases in Egr-2 expression 30 min and 1 h after TNFα treat-
ment were statistically significant (p b 0.05).
To characterize time-dependent Egr-2mRNA expression in neuronal
cells, primary embryonic cortical neurons were treated with mouse re-
combinant TNFα (100 ng/ml) for 0, 0.5, 1, 2, or 4 h. The results show
(Fig. 1B) that, similar to experiments in HeLa cells, the expression of
Egr-2 significantly increases (p b 0.05). In this experiment, increases
were seen 30 min after TNFα treatment as compared to control,
reaching amaximumat 1 h, and then decreasing at 2 and 4 h after treat-
ment. To study the effect of TNFα treatment on EGR-2 protein expres-
sion in neuronal cells, cortical neurons were treated with TNFα (100
ng/ml). We found a trend (n = 3; p N 0.05) toward the increased
EGR-2 protein expression at 4 h after exposure to mouse recombinant
TNFα (100 ng/ml) compared to control (Fig. 1C and D).
2.3. Effects of NF-κB functional blockade on TNFα stimulated Egr-2 expression
in cells
To determine whether the inactivation of NF-κB alters Egr-2 mRNA
expression, SN-50 was administered for 1 h to TNFα-treated HeLa
cells (Fig. 2A). SN-50 is known to block the translocation of the NF-κB
complex to the nucleus (Pannaccione et al., 2005). The results demon-
strate that TNFα significantly increases (p b 0.001) Egr-2 mRNA expres-
sion when compared to HeLa cells not treated with TNFα. The results
further show that the expression of Egr-2 mRNA is significantly de-
creased (p b 0.001) in the presence of the NF-κB inhibitor, SN-50,
when one compares TNFα stimulated cells with or without SN50 treat-
ment. Decreased transcript levels of Egr-2 in TNFα treated cells after
treatment with SN-50 are consistent with the NF-κB dependency of
TNFα-mediated Egr-2 induction.
To determine if blocking NF-κB activation altered Egr-2mRNA expres-
sion in neurons, the NF-κB blocker SN-50 was administered for 12 h in
TNFα treated cortical neurons (Fig. 2B). The data show that TNFα treat-
ment alone significantly increases (p b 0.001) Egr-2 mRNA expression
when compared to untreated cells. Thedata also show that the expression
of Egr-2mRNA is significantly decreased (p b 0.05) in the presence of SN-
50 when one compares all conditions (SN-50 + TNFα vs. TNFα; SN-
50 + TNFα vs. no treatment; SN-50 vs. TNFα; SN-50 vs. no treatment;
TNFα vs. no treatment) except with SN-50 + TNFα vs. SN-50 treatment
alone there is a non-significant decrease (p N 0.05). All experiments
were performed in triplicate. SN50 treatment significantly reduces Egr-2
mRNA expression (p b 0.01) in both TNFα-stimulated cells and in
unstimulated cells compared to TNFα treatment alone.
2.4. Several putative binding sites for NF-κB are found in the Egr-2 promoter
In order to identify potential NF-κB binding sites, we used a bioinfor-
matics approach (http://www.gene-regulation.com ). The 3000 bp im-
mediate upstream sequence of the Egr-2 gene promoter was searchednot p50−/−mice. Genes listed indicates those genes that displayed more than a 2 fold in-
ach fold change valuewas calculated by comparing intensities from theta burst stimulated
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Fig. 1. Time-dependent Egr-2 expression. (A) Egr-2 mRNA expression levels are significantly increased in TNFα-treated HeLa cells as compared to controls. HeLa cells were treated with
mouse recombinant TNFα (5ng/ml) for the indicatedperiods of time.Egr-2mRNA expression levels in TNFα-treated cellswerequantifiedusing qRT-PCRand normalized to GAPDHmRNA
expression at each time point. Values represent mean± SEM (n=4; *p b 0.05). (B) Egr-2mRNA expression levels in TNFα-treated primary cortical neurons are significantly increased as
compared to control. Cortical neuronswere treatedwithmouse recombinant TNFα (100ng/ml) for the indicated periods of time.mRNA fromeachwell containing 1.25× 106 neuronswas
extracted and 1 μg of each RNA sample was reverse transcribed to cDNA. Egr-2 mRNA expression levels in TNFα-treated cells were quantified using qRT-PCR and normalized to Gapdh
mRNA expression at each time point. Values represent mean ± SEM (n=3). *p b 0.05 considered to be significant. (C) Quantification ofWestern blot data (from panel D) shows the ex-
pression of EGR-2 protein trends toward an increase at 4 h after exposure tomouse recombinant TNFα (100 ng/ml) compared to control (no TNFα treatment). Graph is represented as the
ratio of Egr-2/actin (n= 3). Error bars are ± SD. (D) RawWestern blot data of EGR-2 protein expression in cortical neurons after TNFα treatment.
97S. Nafez et al. / Molecular and Cellular Neuroscience 64 (2015) 95–103using P-Match software for possible NF-κB binding sites. Four candidate
NF-κB binding sites with N80% homology to the NF-κB consensus se-
quence were identified within the promoter region of the Egr-2 gene
(Fig. 3). Fig. 3 shows the positions of these binding sites compared to
the transcription start site (TSS).
2.5. The p50 subunit of NF-κB transactivates an Egr-2 promoter reporter
in vitro
To examinewhether p50 is able to transactivate the Egr-2 promoter,
luciferase assays were performed using a reporter driven by the Egr-2
proximal promoter (Fig. 4). The NF-κB p50 subunit potently activated
the promoter compared to the empty vector control (p b 0.05).
2.6. NF-κB subunits occupy the Egr-2 promoter in vivo
To further evaluate and verify Egr-2 transcriptional regulation by
NF-κB, specific NF-κB interactions with the Egr-2 promoter were investi-
gated in vivo, using the ChIP assay with antibodies against the NF-κB p50
subunit and embryonicmouse forebrain tissues.Weused the Egr-2 region
IV given that we found that regions I, II, and III were ChIP negative (data
not shown). Results (Fig. 5) indicate that p50 binds to the NF-κB binding
region IV proximal to the Egr-2 transcription start site (Fig. 3). Given this
result, we chose to focus on the Egr-2 proximal promoter region. Fig. 5Cprovides an additional control demonstrating the lack of NF-κB p50 sub-
unit occupancy of the Egr-2 promoter in p50 knockout tissues in vivo.
2.7. The NF-κB p50 subunit specifically binds to the Egr-2 promoter in vitro
To determine if NF-κB was activated and bound to Egr-2 in our sam-
ples, we conducted EMSA experiments. EMSA results showed specific
binding of recombinant p50 to Egr-2 promoter region IV oligonucleo-
tides containing binding sites in vitro (Fig. 6). Radiolabeled Egr-2 region
IV oligonucleotide probes were incubated alone (lanes 1, 7), with re-
combinant p50 protein (lanes 2–6), with unlabeled Egr-2 probe (lane
5), with p50 antibodies (lane 3: 5 μl antibody, lane 6: 10 μl antibody),
and with nonspecific antibodies (lane 4: 1 μg IgG). Gel shifts, denoting
specific binding of p50 proteins to Egr-2-DNA, are indicated with open
arrowheads. Supershifts with specific p50 antibodies are indicated by
a black solid arrowhead. The symbol I designates nonspecific polyclonal
antibody (IgG). Our findings strongly support specific binding of NF-κB
p50 sub-unit: Egr-2 promoter protein–DNA complexes in vitro.
2.8. Small interfering RNA (siRNA)
To further confirm the results obtained using NF-κB p50 knockout
mice and treatments using the NF-κB blocker SN-50, siRNA knock
down experiments (Fig. 7) were also performed in primary neuronal
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Fig. 2. TNFα stimulated Egr-2 expression and effects of SN50 treatment. (A) Egr-2mRNA ex-
pression levels in TNFα-treatedHeLa S3 cells in the presence of SN50.HeLa cellswere treated
with recombinant mouse TNFα (10 ng/ml) and subsequently with SN50 (100 μg/ml, 1 hour
duration). Values represent mean ± SEM (n=3). *p b 0.001 was considered highly signifi-
cant (TNFα vs. untreated; SN50 + TNFα vs. SN50). (B) Quantitative real-time PCR for Egr-2
mRNA expression after SN50 treatment in cortical neurons. Cortical neurons were treated
with TNFα (100 ng/ml), SN50 (100 μg/ml, 12 hour duration), SN50 (100 μg/ml, 12 hour du-
ration), TNFα (100 ng/ml) or just vehicle. All samples were performed in triplicate as inde-
pendent repeats and were normalized to Gapdh. Error bars represent ± SEMs. *p b 0.001
(TNFα vs. untreated).
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Fig. 4. Regulation of the Egr-2 proximal promoter by the NF-κB p50 sub-unit in vitro. COS7
cells were transiently transfected with a reporter vector comprised of the 1.3 kb proximal
promoter of Egr-2 cloned into pGL3 Basic, or with empty pGL3 Basic. Cells also received
p50 expression vector, or an empty vector control. Luciferase expression was measured
24 h later. All samples were performed in triplicate and were normalized to pGL3 Basic
plus empty expression vector. Error bars represent mean ± SEM. *p b 0.05 vs. pGL3
Basic plus empty vector; #p b 0.05 vs. Egr-2 reporter plus empty vector.
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(Fig. 7B and C). Using this approach, we found that the reduction of
p50 expression by siRNA knockdown resulted in decreased Egr-2
mRNA and protein expression, strongly supporting our other experi-
mental data that the NF-κB transcription factor is required for Egr-2
gene expression.
3. Discussion
The transcription factors Egr and NF-κB have been shown to play
multiple roles in normal and pathological cellular functions. Under-
standing how these factors interact should shed light on how the cellFig. 3. Schematic representation of the transcription factor binding sites in the Egr-2promoter. T
NF-κB binding sites. Transcription Start Site (TSS) represents the first nucleotide (+1) of the Ecreates a coordinated response to environmental changes such as seen
in immune responses and in synaptic plasticity and cognition. Our
data here shows that Egr-2 expression is increased following electrical
stimulation in p50+/+mouse hippocampal slices and that Egr-2 expres-
sion levels are controlled by the transcriptional activity of the NF-κB
transcription factor as measured in HeLa cells and primary neurons.
We previously demonstrated that NF-κB plays a role in synaptic
plasticity (Albensi and Mattson, 2000). In addition, our lab (Oikawa
et al., 2012) and other labs have shown the involvement of NF-κB p50
subunit activity and expression in studies of synaptic plasticity andmem-
ory. In particular, in our study byOikawa et al. we confirmed that LTPwas
induced by theta burst stimulation in hippocampal CA1 subfields. In this
study, using GeneChip® technology we found that Egr-2 expression
was induced by activity-dependent NF-κB activation in p50+/+, but not
in p50−/− hippocampal slices. Moreover, we verified the induction of
Egr-2 upon NF-κB activation through the measurement of Egr-2 mRNA
and protein expression and by analysis of specific NF-κB binding to the
Egr-2 promoter region using non-neuronal and neuronal assay systems.
In addition, using siRNA knockdown techniqueswe observed results con-
sistent with those obtained with p50 knockout mice. Collectively, these
data provide strong evidence for a novel link between NF-κB activation
and Egr-2 expression. These data further suggest that Egr-2 expression
level is directly regulated by the transcriptional activity of NF-κB.
3.1. NF-κB activation
NF-κB signaling and activation have been previously described
(Baldwin, 1996; Mattson, 2005), which showed that NF-κB activation
occurs in the cytosol and is critical for cell functions such as immunity,TSS
hree kilobases of upstreamsequenceof theEgr-2 genepromoterwere searched for putative
gr-2 gene.
A BM       DNA
C
Fig. 5. ChIP assay demonstrating p50 interaction with the NF-κB binding region in vivo.
(A) Chromatin derived from embryonic mouse forebrain was sonicated to fragments of
300–400 bp in size and run on a 1% agarose gel. Ethidium bromide staining of a rep-
resentative gel is shown. (B) DNA representing the most proximal NF-κB binding site
to the transcription start site of the Egr-2 promoter was amplified by PCR from geno-
mic DNA fragments that were precipitated by a p50 antibody. Input shows the non-
immunoprecipitated genomic DNA. (C) Control experiment showing Egr-2 promoter
binding in NF-κB p50+/+ subunit versus NF-κB p50 knockout tissue. Abbreviations:
M = DNA marker; DNA = sonicated DNA.
99S. Nafez et al. / Molecular and Cellular Neuroscience 64 (2015) 95–103inflammation, and brain function. Multiple stimuli including inflamma-
tory cytokines (e.g., TNF), infection, injury, stress, and second messen-
gers such as calcium can induce activation of NF-κB (Pahl, 1999). Once
activated, NF-κB dimers move from the cytoplasm to the nucleus and
occupy NF-κB binding sites in the promoter or enhancer regions of tar-
get genes to regulate their expression. It is generally accepted that
homodimers of p50 or the p50/p52 heterodimer function as transcrip-
tional repressors, whereas the remaining combinations of NF-κB dimers
(e.g., p65/p50) contain at least one monomer of p65, c-Rel, or RelB and
function as activators (Mayeux et al., 1998). Studies have also shown
that the p65/p50 heterodimer binds to DNA much more cooperatively
than homodimer combinations (Mayeux et al., 1998). Some target1 2 3 4 5 6 7
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p50 protein
Antibody -
-
- - -
- I -
- - -
+ -
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Supershifted band:αP50
Specific p50/EGR2 band
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Fig. 6. p50 protein specifically binds to a regulatory element within the Egr-2 promoter
in vitro EMSA demonstrates binding of recombinant p50 to Egr-2 promoter region IV oli-
gonucleotides containing a putative NF-κB binding site in vitro. Radiolabeled Egr-2 region
IV oligonucleotide probes were incubated alone (lanes 1, 7), with recombinant p50 pro-
tein (lanes 2–6), with unlabeled Egr-2 probe (lane 5), with p50 antibodies (lane 3: 5 μl
of antibody, lane 6: 10 μl of antibody), andwith nonspecific antibody (lane 4: 1 μg of poly-
clonal IgG). Gel shifts, denoting specific binding of p50 proteins to Egr-2-DNA, are indicat-
ed with a blue arrow. Supershifts with specific p50 antibodies are indicated by black
arrows. I: nonspecific polyclonal antibody (IgG).genes of NF-κB that play a role in neurodegenerative processes have
been identified (Mattson and Camandola, 2001; Mattson et al., 2000);
however, gene targets of NF-κB in synaptic plasticity and memory re-
main largely unknown. In this study, we first examined potential target
genes that were up- or down-regulated in theta burst stimulated CA1
hippocampal slices from p50+/+ and p50−/−mice.We found that sever-
al genes, including Egr-2, were up-regulated only in p50+/+ samples.
Our GeneChip® data showed a ~3 fold increase in Egr-2 expression fol-
lowing theta burst stimulation, suggesting that EGR-2 is involved in
synaptic plasticity. This finding is consistent with other reports that
found EGR-2 to be involved in the stabilization of LTP (Williams et al.,
1995). Several other genes were upregulated (ranged from 2.1 to 2.5
fold change) in p50+/+ samples as well, which included, Npas4, Usp7,
Rrm2b, Adrbk2, and Scn1a (Table 1).
3.2. NF-κB binding and Egr-2 expression
To confirm the upregulation of Egr-2 gene expression upon NF-κB
activation, we measured Egr-2 mRNA and protein levels in several cell
assays. Our results show an increase in the expression of Egr-2 one-
half hour after TNFα treatment in HeLa cells that reached a maximum
at 1 h. mRNA isolated from TNFα-treated primary cortical neurons
were also used in qRT-PCR experiments tomeasure themouse Egr-2 ex-
pression level changes in TNFα-treated samples versus control. These
results confirmed that, similar to HeLa cells, Egr-2 expression increases
soon after TNFα treatment. Collectively, these results are consistent
with the fact that Egr-2 is an IEG and has a rapid and transient induction
pattern (Single et al., 2000).
We also tested for specific interactions of NF-κB with the Egr-2 pro-
moter using ChIP assays and embryonic forebrain tissues. These exper-
iments demonstrate that NF-κB occupies the NF-κB binding region
closest to the transcription start site of the Egr-2 promoter. To our knowl-
edge, no previous studies have shown that NF-κB binds to this region
in vivo. Importantly, prior studies (Mayeux et al., 1998) have shown
that unlike most transcription factors, NF-κB dimers do not use any sec-
ondary structures for contacting DNA, so it is likely that NF-κB binds to
the Egr-2 promoter without the participation of additional complexes.
3.3. Egr-2 in cellular function
What role might Egr-2 play in the cell? In general, Egr proteins have
been shown to play roles in cellular growth and differentiation. In
human studies, mutations involving EGR-2 have been found in patients
with inherited peripheral neuropathy (Bellone et al., 1999). Further-
more, in mouse models, Egr-2 has been shown to play a role in the reg-
ulation of peripheral nerve myelination (Topilko et al., 1994). Nickols
et al. (2003) also showed that NF-κB plays a role in themyelination pro-
cess in Schwann cells where Egr-2 expression, up-regulated early in the
myelination process, may be a critical regulator of genes encoding the
proteins mediating myelination (Jessen and Mirsky, 2002). The induc-
tion of Egr-2 mRNA or protein has also been demonstrated following
seizure activity (Bhat et al., 1992) and focal cerebral ischemia (An et al.,
1992). Other studies show that EGR-2 protein can also exist in both cyto-
plasm and nucleus (Herdegen et al., 1993b,1993c). However, the zinc fin-
gers of the EGR-2 protein each contain a nuclear localization signal
(Matheny et al., 1994) and thisDNA sequencemight be involved innucle-
ar localization of the EGR-2 proteins (Beckmann and Wilce, 1997).
Several studies (Cole et al., 1989;Williams et al., 1995;Worley et al.,
1993; Yamagata et al., 1994) have been conducted that have implicated
Egr-2 in multiple brain functions, including developmental processes,
immunity, apoptosis, and cognition. In particular, Worley et al. found
that Egr-2 expression increased in hippocampal neurons after LTP in-
duction (Worley et al., 1993). Other recent studies have also shown an
interaction between CREB (cAMP responsive element binding protein)
binding protein (CBP) and EGR-2 protein (Yoo and Lee, 2004). In addi-
tion, Lemberger et al. (2008) showed that in mouse forebrain neurons,
A50kd Egr-2
47kd NFkb p50
1         2         3       4        5
GAPDH
B
GAPDH
Egr-2
NFkb p50
C
Fig. 7.Representative NF-κB p50 subunit knock-down experiment using siRNA. (A) An siRNA pool targeting p50was transfected into primarymouse embryonic cortical neurons. Neurons
were incubated for 2 days and their RNAs were extracted, reverse transcribed to cDNA and subjected to qRT-PCR to assess the expression of Egr-2 after NF-κB p50 subunit knock-down.
Results show a dramatic decrease in Egr-2 expression level in neurons transfectedwith p50 siRNA consistent with the role of NF-κB in the induction of the Egr-2 gene expression (n= 3).
(B, C) siRNA targeting of p50 was compared to treatment for 1 h using SN50 (100 μg/ml), inactive SN50M (50 μg/ml), and compounds in human SKNBE(2) neuroblastoma cells
in vitro. NF-κB p50, Egr-2 and GAPDH levels were compared at the mRNA (B) and protein levels (C).
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necessary for the expression of the Egr-2 gene. Still other studies report
protein–protein interactions between NF-κB p50 and p65 subunits and
CREB binding protein (Cao et al., 2006; Sung et al., 2004; Zhong et al.,
2002) suggesting a complex interplay among these transcription
factors.
3.4. Limitations and future directions
Overall, our data provide strong evidence for a link between NF-κB
activation and subsequent Egr-2 expression, which is important for un-
derstanding patterns of gene expression in neuronal and non neuronal
cells.
We found that SN-50 treatment significantly reduces Egr-2 mRNA
expression (p b 0.01) in both TNFα-stimulated cells and in unstimulated
cells compared to TNFα treatment alone. Similar results were obtained
in SKNBE(2) neuroblastoma cells when comparing SN50 (Calbiochem
481480) and SN50M, an inactive SN50 compound (Calbiochem 481486)
(Fig. 7B, C). However, a few questions remain concerning the patterns
of expression in specific cases. For example, in Fig. 2B, the application
of SN-50 (NF-κB inactivator) in TNFα-treated cortical neurons ap-
peared to have no effect on Egr-2 mRNA expression; however, SN-
50 application in TNFα-treated non-neuronal HeLa cells (Fig. 2A)
and SKNBE(2) neuroblastoma cells (Fig. 7B) did show a significant
decrease in Egr-2 mRNA expression. Although we cannot explain this
finding in the treated primary neurons, one possibility is that this is due
to a concentration-related effect. Also, if one compares this finding to
Fig. 5B where NF-κB p50 subunit activity was suppressed by siRNA, Egr-
2mRNA expression levelswere relatively lower than in untreated cortical
neurons (Fig. 2), which implies that NF-κB activity was more efficientlyblocked by siRNA than SN50, which might be expected. It is also worth
commenting on the specificity of SN50 (Boothby, 2001). SN50 has been
used widely as an inhibitor of NF-κB. However, a few years ago, it was
found that SN50 is not necessarily specific for p50 or for NF-kB transcrip-
tion factors in general. Data shows that SN50 also blocks the nuclear in-
duction of the transcription factors STAT, AP-1 and NFAT (Boothby,
2001). Since these other factors were not directly assessed in this study,
it is unlikely that this non-specificity of SN50 has major importance in
this study.
Although we found a direct relationship between NF-κB activation
and Egr-2 expression, we acknowledge the possibility that the entire
network of protein–protein interactions in this context could be much
more complex. Future studies to address this question could use mice
that overexpress Egr-2 to determine whether Egr-2 overexpression res-
cues selective deficits observed in p50−/−mice. Furthermore, it should
be noted that TNFα is known to have other activation pathways as
well, which could have influenced our findings in unknownways. Final-
ly, since p50 homodimers have been shown to repress transcription, we
cannot rule out the possibility that in the absence of p50 one might see
an elevated NF-κB-mediated transcriptional activity.
Furthermore, in this studywe did not examine Egr-1, Egr-3, or Egr-4.
Therefore, future studies would be warranted that also evaluate Egr-1,
Egr-3, and Egr-4, in parallel with Egr-2, which may lend insight into po-
tential differences among these isoforms and whether NF-κB activity is
linked to the expression of these other isoforms.
4. Conclusions
In conclusion, our data show that Egr-2 expression is increased fol-
lowing theta burst stimulation in p50+/+ mouse hippocampal slices
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tional activity of the NF-κB transcription factor as measured in non-
neuronal and neuronal cells. Further studies are warranted that investi-
gate the functions of NF-κB and EGR-2 in the whole animal and that
determine the temporal dynamics of the gene regulation process in-
volving these factors.
5. Experimental methods
5.1. Animal model
Two month-old homozygous NF-κB p50 knockout mice (B6;129P2-
Nfkb1tm1Bal/J) (p50−/−) and the controls (B6129PF2/J) (p50 +/+) were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Targeted
disruption of the NF-κB p50 subunit has previously been described in de-
tail (Sha et al., 1995). These mice are incapable of producing the p50 pro-
tein. Mice homozygous for the Nfkb1tm1Bal targeted mutation are viable.
Homozygous mutant mice exhibit ineffective responses to infection, de-
fective B cell responses, and abnormalities in basal and specific antibody
production. Timed pregnant wild-type CD1 mice were purchased from
Central Animal Care at the University of Manitoba. Miceweremaintained
on a 12 hour light/12 hour dark cycle at 22 °C in the pathogen-free an-
imal facility at the St. Boniface Research Centre. Mice were tested at
9–10 weeks of age. The University of Manitoba Animal Care Committee
approved all procedures, which conformed to guidelines published by
the Canadian Council on Animal Care.
5.2. Preservation of brain slices for microarray analysis
We previously showed (Oikawa et al., 2012) that mice with NF-κB
p50−/− subunit deletion had deficits in late LTP in vitro and impairments
in retention in the Morris water maze as compared to p50+/+ mice. To
evaluate brain samples using Affymetrix Mouse DNA microarrays
(Affymetrix, Santa Clara, CA, USA), we used hippocampal slices from
this prior study (Oikawa et al., 2012) that were stimulated with LTP-
inducing protocols (theta burst stimulation). For every hippocampal
slice that was used in the present study, LTP was confirmed. These hip-
pocampal slices (which included CA1, CA3 and dentate gyrus subfields)
were then preserved for microarray analysis according to the
manufacturer's instructions; that is, 3 h after stimulation, hippocampal
slices that were stimulated versus unstimulated control slices from
both p50-/− and p50+/+ mice were stored in RNAlater (4 °C) immedi-
ately following stimulation for analysis. Changes in gene expression as-
sociated with LTP responses at three or more hours have been
previously demonstrated by several labs (Abraham et al., 1991;
Alberini, 2009; Barco et al., 2005; Kandel, 2001).
5.3. Affymetrix mouse DNA microarrays
GeneChip Mouse Genome 430 2.0 microarrays (Affymetrix, Santa
Clara, CA, USA) were used for gene expression analysis. Total RNA was
pooled from five hippocampus slices (either stimulated or unstimulated,
from p50+/+ or p50−/−mice) and prepared for microarray hybridization
as per the manufacturer's instructions. Results were collected and
analyzed using GeneChip Operating System software. Fold change
values were calculated by comparing intensities from stimulated
and unstimulated slices using robust multi-array averaging.
5.4. Cell culture and maintenance
HeLa S3 cells were cultured in Dulbecco's Modified Eagle's Me-
dium (DMEM, Gibco) supplemented with 10% fetal bovine serum
(FBS, Hyclone) and 1% penicillin–streptomycin solution (Gibco).
SKNBE(2) human neuroblastoma cells were routinely grown in
DMEM-F12 medium containing 1% penicillin–streptomycin solution and
10% heat inactivated fetal calf serum. Cellsweremaintained asmonolayercultures at 37 °C in a humidified incubator with 5% CO2. Experiments
were performed on days 7–8. To culture primary cortical neurons, fetal
brains of timed-pregnant CD-1 mice at gestational days 16–18 were re-
moved and cerebral corticeswere dissociated by gentle pipetting. Dissoci-
ated tissue was filtered using a 40 μm cell strainer (BD Falcon), washed
and suspended in Neurobasal medium (GIBCO) with B27 supplement
(GIBCO), 5% FBS (Hyclone), 1.2 mM glutamine and 5 mM HEPES. Cells
were plated at 5 × 105 cells/cm2 on poly-D-lysine-coated plates (NUNC,
VWR). Twenty four hours after plating, 2 mM Cytosine Arabinoside
(Ara-c, Sigma) was added to inhibit non-neuronal cell growth. Subse-
quently, medium was completely replaced after another 24 h with
Neurobasal/B27. Cortical neurons were cultured 7–9 days in vitro before
treating with SN50 or TNFα.
5.5. RNA isolation and quantitative real-time PCR (qRT-PCR)
HeLa S3 cells or primary cortical neurons were treated with
5–100 ng/ml of TNFα at different time points. RNA was isolated
from HeLa S3 cells with AllPrep DNA/RNA/Protein Mini Kit (QIAGEN)
and TRIZOL was used for RNA extraction from primary cortical neurons
as per the manufacturer's instructions. One microgram total RNA was re-
verse transcribed to cDNA using the Bio-Rad iScriptTM cDNA Synthesis
kit. The cDNA mixture was subjected to real-time PCR with the Biorad
iQ SYBR Green Supermix and the iCycler iQ® real-time system using the
primers listed in Supplemental Table 1. The qRT-PCR running protocols
for mouse Egr-2 and Gapdh are listed in Supplemental Table 2. Melt
curve analyses verified the formation of single desired PCR products. For
quantification of Egr-2 gene expression changes, the Pfaffl method
(Real-Time PCR Applications Guide from Bio-Rad) was used to calculate
relative fold changes normalized against the Gapdh gene.
5.6. Protein extraction
Proteins of TNFα-treated HeLa cells were extracted using Allprep/
DNA/RNAMini kit (QIAGEN) following the manufacturer's instructions.
For the TNFα-treated primary cortical neurons, after collecting the
media, 60 μl lysis buffer containing 50 mM Tris–HCl pH 6.8, 2% SDS
and 1× Protease Inhibitor (PI) Cocktail (Roche) was added to each
well. Using a cell scraper, neurons were transferred to a 1.5 ml tube on
ice. To lyse the cells, all samples were frozen in liquid nitrogen and
thawed four times. To remove intact cells and membrane, the samples
were centrifuged in an Eppendorf 5810 R centrifuge at a maximum
speed for 15min at 4 °C. The supernatant from the cell lysate containing
proteins was transferred to new tubes.
5.7. Western blotting
NuPAGE® Bis-Tris, 4–12% Mini Gels (1 mm thickness— Invitrogen)
were used for electrophoresis of proteins. Aliquots of proteins
(10–80 μg) were prepared and separated on NuPAGE gels at a constant
voltage (100 V) for 120 min following the instructions of the NuPAGE®
technical guide. Proteins separated on NuPAGE gels were transferred
onto PVDF membrane using a Trans-Blot SD Semi-Dry Electrophoretic
Transfer Cell (Bio-Rad) following the manufacturer's instructions. Trans-
fer was carried out at a constant voltage (20 V) for 35 min at room tem-
perature. After blocking with 5% skim-milk in TBS solution containing
0.2% Tween-20 (TBST) overnight at 4 °C, the membrane was incubated
with a rabbit anti-EGR-2 polyclonal antibody (Covance Research Prod-
ucts, Inc., San Diego, CA, USA), diluted in TBST containing 1% skim milk,
overnight with gentle shaking at 4 °C. The membrane was washed 4
times in 30 min (15 min followed by 3 × 5 min) with TBST containing
1% skimmilk. After the lastwash, the blotwas incubatedwith a secondary
antibody, goat anti-rabbit IgG conjugated with horseradish peroxidase
(HRP) from Santa Cruz, diluted 1:6500 in TBST at room temperature for
1 h. Themembranewas thenwashedwith TBST only. The chemilumines-
cence signal was visualized using the ECL-Plus detection system (GE
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sitometry was performed on all blots. Standard curves were generated to
ensure that the density of the bands fell within the linear range. The spec-
ificity of the Egr-2 antibody has been previously described (Dillon et al.,
2007).5.8. Analysis of κB-binding sites within the Egr-2 promoter
The mouse Egr-2 upstream sequence information was obtained
from the Ensemble website (http://www.ensembl.org/, gene ID:
ENSMUSG00000037868). Using the P-Match program (http://www.
gene-regulation.com/), 3000 bp of the immediate upstream sequence of
the Egr-2 gene promoter was searched for putative NF-κB binding sites.
Primers targeting these regions were designed using Primer 3 software
and used for chromatin immunoprecipitation (ChIP) analysis. Moreover,
the primer sequences were analyzed using the BLAST-like alignment
tool (http://genome.ucsc.edu/) which confirmed that these oligonucleo-
tide sequences contained 100% homology to sequences within the Egr-2
gene without homology to any other known sequences in the mouse
genome.5.9. Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed as
previously described (Zhou et al., 2004) with the whole forebrains of
CD-1mice (E16–E18) using a p50 primary antibody (Santa Cruz) to im-
munoprecipitate protein–DNA complexes. The DNA was extracted
using a Qiaquick PCR purification kit (QIAGEN) following the
manufacturer's instructions. Approximately 10% of the precipitated
DNA was used for PCR detection using the primers targeting the four
NF-κB binding sites on the promoter region of the Egr-2 gene listed in
Supplemental Table 3, 10% of 5 M Betaine and the running protocol
listed in Supplemental Table 4. Sample without added antibody was
used as a negative control and non-immunoprecipitated genomic DNA
(input) was used as a positive control for each condition tested. ChIP
was also performed using p50−/− forebrain tissues as an additional neg-
ative control. Bands obtained from PCR following ChIP were isolated,
subcloned and sequenced to confirm target gene identity.5.10. Electrophoretic mobility shift assay (EMSA)
We used the Egr-2 promoter region IV (the NF-κB binding region
most proximal to the transcription start site identified by ChIP as a pu-
tative NF-κB binding site in vivo). This region was subcloned into the
pCR™4-TOPO® vector for sequencing (Invitrogen). Following EcoRI
restriction enzyme digestion, the plasmid was run on a 2% agarose gel
and purified (Qiagen gel purification kit). The double stranded DNA frag-
ment (0.5 μg) was radiolabeled with 2 μl 32P-dATP (Perkin Elmer) using
2 units of Klenow large fragment of DNA Polymerase I (Invitrogen) at
37 °C for 30 min. The labeled probe was purified with illustraTM
MicroSpin TMG-25Columns (GEHealthcareUK). The gel shift binding re-
action mixture (total volume 20 μl) contained 1 μg recombinant protein
(NF-κB subunit (residues 35–381) untagged, human recombinant,
BIOMOL International), 1 μg poly(dI-dc), 0.2 μl PMSF (100 mM), and
0.2 μl 1% BSA in 1× EMSA binding buffer (Promega). Excess unlabeled
probe was added for “cold competition” and for supershift experiments,
a specific polyclonal anti-p50 antibody (NF-κB p105/p50, Epitomics) or
a nonspecific antibody for control was used. The binding reaction was in-
cubated for 30 min at room temperature, and then labeled probe
(100,000 CPM) was added to the reaction and incubated for another
20 min. The whole reaction (20 μl) was run on a 4% acrylamide/
bisacrylamide gel with 0.5× TBE buffer at 300 V and the gel was stored
at−80 °C. Kodak film (X-Omat™-LS) was used for autoradiography.5.11. Luciferase reporter assay
The Egr-2 promoter luciferase construct containing 1.3 kb sequence
upstream of the transcription start site cloned into pGL3 Basic has been
described previously andwas obtained fromAddgene (Kao et al., 2009).
COS7 cells in 6-well plates (8 × 105 cells/well) were grown to 90%
confluence in high-glucose DMEM supplemented with 10% FBS,
1% L-glutamine and 1% penicillin–streptomycin at 37 °C. Medium
was removed and cells were washed with 1× PBS, then 1.5 ml Opti-
Mem was added to each well followed by a 30 minute incubation. Cells
were transfected with Lipofectamine (Invitrogen) plus 500 ng plasmid
and 5 ng pRL Renilla luciferase transfection control plasmid as per
manufacturer's directions. Cells were maintained at 37 °C for 24 h, medi-
um removed and lysed for the luciferase assay using the Dual-Luciferase
Reporter System (Promega) according to the manufacturer's directions.
Each sample was assayed in duplicate, and three individual experiments
were carried out. Results were normalized to pRL expression.
5.12. Small interfering RNA (siRNA)
Timed-pregnant CD-1 mice were used to generate primary cortical
neuron cultures (see above). Neocortex was dissected and collected in
Hank's Balanced Salt solution (HBSS). The tissue was incubated for
10 min at room temperature with 0.05 mg/ml trypsin (GIBCO). The cells
were pelleted by centrifugation (1200 rpm, 5 min), then resuspended
and gently triturated to a single cell suspension in HBSS containing
100 μg/ml DNase I (Sigma). The cell suspension was transferred to a
tube containing Neurobasal medium with B-27 (GIBCO) and penicillin–
streptomycin–fungizone (100 U/ml) (Life Technologies). Cells were
counted and 3×105 cells were plated per well (poly-D-lysine coated 24
well plates (Cel-lines Associates, Inc.)) and cultured at 37 °C with 5%
CO2. NF-κB p50 siRNA (sc-29408, Santa Cruz Biotech) and control siRNA
(sc-37007)were obtained. The siRNAs consist of pools of three tofive spe-
cific 19–25 nucleotide siRNAs designed to knock-down NF-κB p50 gene
expression. Transient transfection using siRNA transfection reagents (sc-
45064) was carried out on culture day 2 in vitro. Ten picomoles (1 μl) of
siRNAwas added perwell on 24well plates following the siRNA transfec-
tion protocol. Forty-eight hours after transfection, cellswerewashedwith
cold PBS twice and subjected to qRT-PCR. The SKNBE(2) cellswere seeded
onto 60mm2 dishes ~70% confluent on the second day and siRNA control
(sc-36869) or NFκb p50 siRNA(h) (sc-29407) was applied. Transient
transfection using Lipofectamine 2000 reagent was carried out on culture
day 2. One hundred picomoles (100 μl) of siRNAwas added to each plate
following the siRNA transfection protocol.
5.13. Statistical analyses
Some analyses were performed by the Student's t-test (two-sided)
with a 95% confidence interval. LTP experiments were analyzed using
mixedmodel ANOVAand post hoc special effect t testwhen appropriate.
SPSS Software v13 (SPSS Inc., Chicago, IL, USA) was used for most anal-
yses. p b 0.05 was considered significant in all cases. For Western blot-
ting data, band intensities were quantified using ImageJ software
(http://rsbweb.nih.gov/ij/) and data are expressed as S.E.M. or S.D. as in-
dicated in each case.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.mcn.2014.12.008.
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